MedPath

MR Elastography versus FibroScan for the non-invasive assessment of liver fibrosis in patients with chronic liver disease

Conditions
liver fibrosis
scarring of liver parenchyma
10019654
Registration Number
NL-OMON33250
Lead Sponsor
Academisch Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
95
Inclusion Criteria

Patients over 18 years of age;
Patients suspected of chronic viral or chronic non-alcoholic liver disease with an indication for liver biopsy (ASAT elevated >60 mmol/l (n<=40 mmol/l));
Written informed consent

Exclusion Criteria

Patients under 18 years of age;
Alcohol consumption of >3 units/day for males and >2 units/day for females;
Patients who are pregnant;
Patients who are claustrophobic (MRI scanner);
Patients who have magnetic or radiofrequency sensitive implants (MRI scanner);
Patients with extreme obesity (MRI scanner)

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Assessment of the diagnostic accuracy of MR Elastography in diagnosing liver<br /><br>fibrosis compared with FibroScan and histopathology in patients suspected of<br /><br>chronic viral liver disease and non-alcoholic fatty liver disease. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>*The feasibility of combining MR Elastography and proton MR Spectroscopy in<br /><br>non-alcoholic fatty liver disease to distinguish between simple steatosis and<br /><br>NASH.<br /><br>*The evaluation of antiviral treatment response with combined MR Elastography<br /><br>and MR Spectroscopy versus FibroScan in patients with chronic viral liver<br /><br>disease.<br /><br>*The influence of increased hepatic fat content and inflammatory activity on<br /><br>viscoelasticity measurements.<br /><br>*The burden of liver biopsy, MR Elastography and FibroScan.</p><br>
© Copyright 2025. All Rights Reserved by MedPath